KM Research Hub
← 返回论文库
待处理 入排:符合 图源:待检查 入排置信度 0.96

Nivolumab + Doxorubicin, Vinblastine, and Dacarbazine in HIV-Associated Advanced-Stage Classic Hodgkin Lymphoma.

Gaurav Goyal, Kathryn Lurain, Gabby Lopez, Sarah C Rutherford, Sharon Castellino, Kelly Davison, Andrew Evens, Sonali M Smith, Kara Kelly, Michael LeBlanc, Joo Y Song, Thomas Odeny, Lee Ratner, Jonathan W Friedberg, Alex F Herrera

JCO Oncol Adv 3(1) e2500143

PMID42577949
PMCIDPMC13456540
DOI10.1200/oa-25-00143
发表日期2026-08-11
入排依据:明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
摘要

摘要

PURPOSE: S1826 was an international phase 3 randomized trial that demonstrated improved progression-free survival of nivolumab plus doxorubicin, vinblastine, and dacarbazine (N+AVD) over brentuximab vedotin plus AVD (BV+AVD) in newly diagnosed advanced stage classic Hodgkin lymphoma (cHL). Here we report results of enrolled participants with HIV. PARTICIPANTS AND METHODS: People with HIV (PWH) with a CD4+ T-cell above ≥200 cells/μL and on effective ART with an undetectable HIV viral load within 6 months prior to enrollment were eligible. Participants were randomly assigned in a 1:1 ratio to receive six 28-day cycles of either N+AVD or BV+AVD intravenously. The primary endpoint was progression-free survival. RESULTS: 16 eligible PWH were enrolled, 11 received N+AVD and 5 received BV+AVD. The median follow-up duration was 32.7 months in the N+AVD arm and 26.7 months in the BV+AVD arm. The 2-year PFS rate was 77.9% in N+AVD arm and 75.0% in the BV+AVD arm. The 2-year OS was 85.7% in the N+AVD arm and 75.0% in the BV+AVD arm. Grade ≥ 3 adverse events were observed in 45% of participants in the N+AVD arm and 50% in the BV+AVD arm with more frequent febrile neutropenia, and severe infections observed in the BV+AVD arm. CONCLUSIONS: N+AVD is safe and effective in newly diagnosed HIV-associated advanced stage cHL. Clinicaltrials.gov number NCT03907488.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。